Clinipace, a software company focused on late-stage clinical research studies and patient registries, is working with a Texas-based company on an advanced mechanical heart valve study.
Medical Carbon Research Institute retained Clinipace to support the Phase IV study as approved by the Food and Drug Administration.
The valve could become the first one approved for use with low-dose anticoagulation therapy.
Some 225,000 people receive heart valves annually around the world.
Clinipace will use its web-based technology platform known as Tempo to collect and manage data from several resource sources that are part of the study.